NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES)

Volume 7 Issue 2 Page 146-151, 2026

ONLINE ISSN:2992-5819 PRINT ISSN:2992-6149

Open Access

https://doi.org/10.59298/NIJSES/2026/72.146151

Impact of Metabolic Disease on Hepatic Vulnerability: Why Diabetic Livers Injure More Easily

Muhindo Anitah

Department of Pharmacy Kampala International University Uganda
Email: anitah.muhindo@studwc.kiu.ac.ug

ABSTRACT

Metabolic diseases, particularly diabetes mellitus, significantly increase hepatic vulnerability to injury from drugs, toxins, and ischemic or inflammatory stress. Diabetic livers are characterized by insulin resistance, dysregulated lipid and glucose metabolism, chronic low-grade inflammation, oxidative stress, and altered mitochondrial function, creating a permissive environment for hepatocellular damage. These metabolic derangements disrupt normal hepatocyte adaptive mechanisms, reduce antioxidant defenses, and promote pro-inflammatory signaling, rendering the liver more susceptible to injury. Clinical and experimental evidence demonstrates that diabetic individuals exhibit increased incidence and severity of drug-induced liver injury, nonalcoholic steatohepatitis progression, and ischemia-reperfusion damage. Understanding the mechanisms underlying this heightened vulnerability, including mitochondrial dysfunction, endoplasmic reticulum stress, lipotoxicity, and altered immune responses, provides a foundation for risk stratification, preventive strategies, and therapeutic interventions. This review synthesizes current knowledge on the impact of metabolic disease on liver susceptibility, highlighting mechanistic pathways and clinical implications, and underscores the need for targeted approaches to protect the diabetic liver from injury.

Keywords: Diabetes mellitus, hepatic vulnerability, oxidative stress, mitochondrial dysfunction, lipotoxicity

INTRODUCTION

The liver is a central metabolic organ that regulates glucose and lipid homeostasis, detoxifies xenobiotics, synthesizes plasma proteins, and participates in immune surveillance [1]. In the context of metabolic diseases, particularly type 2 diabetes mellitus and obesity-associated insulin resistance, hepatic metabolic and structural homeostasis is profoundly altered, predisposing the organ to injury from drugs, toxins, ischemia, or inflammatory insults [2]. Epidemiological and clinical studies demonstrate that diabetic patients are at increased risk of drug-induced liver injury, accelerated progression of nonalcoholic fatty liver disease, steatohepatitis, and worse outcomes in viral hepatitis or ischemia-reperfusion injury [3]. The heightened vulnerability of diabetic livers is multifactorial. Chronic hyperglycemia, dyslipidemia, and insulin resistance induce persistent low-grade inflammation, oxidative stress, and endoplasmic reticulum stress, creating a pro-oxidative and pro-inflammatory hepatic microenvironment [4]. These factors compromise hepatocyte adaptive capacity and diminish resilience to metabolic or xenobiotic stress. Mitochondrial dysfunction, impaired autophagy, and accumulation of lipotoxic intermediates further exacerbate cellular injury [5]. Understanding how these metabolic derangements interact to sensitize the liver is essential for developing preventive strategies, tailoring pharmacotherapy, and designing targeted interventions. This review provides a comprehensive analysis of the molecular, cellular, and systemic pathways through which metabolic disease increases hepatic vulnerability, highlighting mechanisms that underlie enhanced liver injury in diabetes.

2. Metabolic Disease and Hepatic Vulnerability

Metabolic diseases, particularly type 2 diabetes mellitus and obesity-related insulin resistance, profoundly alter hepatic physiology and increase susceptibility to injury [6]. Insulin resistance disrupts normal hepatocyte metabolic regulation, impairing glycogen synthesis and failing to suppress gluconeogenesis. These changes lead to persistent hyperglycemia and increased influx of free fatty acids into the liver [7]. Excess fatty acids are esterified into triglycerides, resulting in hepatic steatosis, which itself promotes oxidative stress and sensitizes hepatocytes to injury. Dyslipidemia further compounds this vulnerability [8]. Elevated circulating triglycerides, free fatty acids, and lipotoxic intermediates such as ceramides and diacylglycerols disrupt mitochondrial function, promote endoplasmic reticulum stress, and activate stress-responsive signaling pathways, including c-Jun N-terminal kinase and protein kinase C. This lipotoxic environment amplifies hepatocyte susceptibility to apoptosis, necrosis, and fibrogenic responses, accelerating progression toward steatohepatitis and fibrosis [9]. Chronic low-grade inflammation is a hallmark of metabolic disease. Adipose tissue and liver-resident immune cells secrete pro-inflammatory cytokines such as TNF-α, IL-6, and MCP-1, which recruit and activate Kupffer cells, further exacerbating oxidative stress [10]. The combination of metabolic dysregulation, lipotoxicity, and inflammation creates a primed liver that responds to additional stressors, including drugs, toxins, or ischemic events, with exaggerated injury.

3. Oxidative Stress in the Diabetic Liver

Oxidative stress is central to the increased vulnerability of diabetic livers [11]. Hyperglycemia and excess free fatty acids enhance mitochondrial ROS production, while reduced antioxidant capacity diminishes the ability to neutralize reactive oxygen species. Mitochondrial overload and electron transport chain dysfunction lead to further ROS generation, creating a self-perpetuating cycle of oxidative damage [12]. ROS induce peroxidation of lipids, oxidation of proteins, and DNA damage, impairing hepatocyte function and triggering cell death pathways [13]. Oxidative stress also activates redox-sensitive transcription factors, such as NF-κB, which maintain a pro-inflammatory state. Importantly, the oxidative environment lowers the threshold for hepatocyte injury in response to xenobiotics, ischemia, or infection [14]. This explains why diabetic patients exhibit increased incidence and severity of drug-induced liver injury, more rapid progression of nonalcoholic steatohepatitis, and heightened susceptibility to ischemic or inflammatory liver insults. Collectively, metabolic dysregulation, lipotoxicity, chronic inflammation, and oxidative stress act in concert to compromise hepatocyte resilience, establishing the diabetic liver as a highly vulnerable organ.

4. Mitochondrial Dysfunction

Mitochondria are both primary sources and key targets of oxidative stress in diabetic livers [15]. Chronic hyperglycemia and excess free fatty acids increase substrate flux into mitochondria, overloading the electron transport chain and enhancing electron leakage, which generates reactive oxygen species. Mitochondrial membrane potential is frequently disrupted in diabetes, impairing ATP synthesis and reducing hepatocyte energy reserves [16]. Disrupted mitochondrial function also triggers the release of pro-apoptotic factors, such as cytochrome c, which activate caspase-dependent cell death pathways. Impaired β-oxidation further promotes lipid accumulation, exacerbating steatosis and lipotoxicity [17]. Additionally, diabetic livers often exhibit reduced mitophagy and defective mitochondrial quality control, preventing the removal of damaged mitochondria and perpetuating oxidative stress [18]. Collectively, these mitochondrial impairments lower the threshold for hepatocyte injury in response to xenobiotics, ischemia, or inflammatory stimuli.

5. Endoplasmic Reticulum Stress and Immune Dysregulation

Endoplasmic reticulum (ER) stress is another hallmark of diabetic liver pathology [19]. Excess lipid accumulation and oxidative stress disrupt protein folding, activating the unfolded protein response (UPR). While adaptive UPR initially attempts to restore ER homeostasis, prolonged ER stress leads to apoptosis via CHOP-mediated pathways [20]. ER stress also interacts with mitochondrial dysfunction, amplifying oxidative damage and cellular vulnerability. Immune dysregulation further compounds hepatocellular susceptibility [21]. Diabetes is associated with chronic low-grade inflammation, characterized by elevated cytokines such as TNF-α, IL-6, and MCP-1. These mediators recruit and activate Kupffer cells and other immune effectors, which produce additional reactive oxygen species and pro-inflammatory signals [22]. Impaired resolution of inflammation in diabetic livers prolongs tissue stress and amplifies injury. Together, ER stress and immune dysregulation synergize with metabolic and mitochondrial defects, creating a primed hepatic environment that is highly susceptible to injury from drugs, toxins, or ischemic events.

6. Drug-Induced Vulnerability in Diabetic Livers

Diabetic livers are particularly susceptible to drug-induced liver injury (DILI) due to pre-existing metabolic, oxidative, and inflammatory stress [23]. Drugs that undergo extensive hepatic metabolism, such as acetaminophen, statins, and certain antiretrovirals, produce reactive intermediates or deplete glutathione, amplifying oxidative stress [24]. In diabetes, increased CYP2E1 activity and mitochondrial overload further

enhance the generation of reactive oxygen species, lowering the threshold for hepatocyte injury [25]. Additionally, lipotoxicity and chronic ER stress sensitize hepatocytes to apoptosis and necrosis following drug exposure. Mitochondrial dysfunction in diabetic livers impairs ATP production and β-oxidation, reducing the organ's capacity to detoxify reactive metabolites [26]. These factors collectively explain why diabetic patients often experience more severe or rapid-onset DILI compared to non-diabetic individuals.

7. Clinical Implications

The enhanced vulnerability of diabetic livers has several important clinical consequences [27]. First, drug safety requires careful consideration, including dose adjustments, monitoring of liver function tests, and avoidance of potentially hepatotoxic medications whenever possible [28]. Second, diabetes accelerates progression from simple steatosis to nonalcoholic steatohepatitis (NASH) and fibrosis, increasing the risk of cirrhosis and hepatocellular carcinoma [29]. Third, ischemic or surgical insults, including liver resection or transplantation, produce worse outcomes in diabetic patients due to impaired regenerative capacity, oxidative stress, and inflammation [30]. Therapeutic strategies targeting these vulnerabilities can mitigate risk. Glycemic and lipid control reduces metabolic and oxidative stress. Antioxidants, mitochondrial protectants, and ER stress modulators may support hepatocyte resilience. Lifestyle interventions, including diet and exercise, further decrease systemic and hepatic inflammation, lowering susceptibility to injury.

8. Strategies to Reduce Hepatic Vulnerability

Preventive and therapeutic strategies focus on restoring metabolic, oxidative, and cellular homeostasis [31]. Optimizing glycemic control limits hyperglycemia-driven ROS production and lipotoxicity. Managing dyslipidemia reduces fatty acid overload and ER stress [32]. Antioxidants, such as N-acetylcysteine or vitamin E, support redox balance, while compounds targeting mitochondrial function, such as coenzyme Q10 or mitochondrial-targeted peptides, enhance cellular resilience [33]. Pharmacologic or nutritional interventions that modulate ER stress and improve protein folding may further protect hepatocytes. Combining these approaches with lifestyle modifications-weight loss, exercise, and balanced nutrition-can attenuate systemic and hepatic inflammation [34]. Ultimately, integrated strategies targeting metabolic, oxidative, and inflammatory pathways are essential to reduce liver injury risk in diabetic patients, improve clinical outcomes, and prevent progression to severe liver disease.

9. Future Directions

Advancing our understanding of hepatic vulnerability in diabetes requires a multi-faceted research approach [35]. Systems biology and computational modeling can map complex interactions between metabolic stress, oxidative pathways, ER stress, and immune activation, identifying key nodes that drive hepatocyte injury [36]. Development of integrative biomarker panels, combining indicators of oxidative stress, inflammation, lipid overload, and genetic susceptibility, could enable early detection and risk stratification in diabetic patients before overt liver injury occurs [37]. Personalized medicine approaches, incorporating individual metabolic profiles, genetic polymorphisms, and comorbidities, may guide tailored therapeutic interventions and drug dosing to minimize hepatic risk [38]. Additionally, clinical trials investigating mitochondrial protectants, antioxidants, and ER stress modulators are essential to translate mechanistic insights into effective therapies [39]. Combining these strategies with lifestyle interventions targeting glycemia, lipid metabolism, and systemic inflammation holds promise for reducing liver injury, improving patient outcomes, and preventing progression to advanced liver disease in diabetes.

CONCLUSION

Diabetes and related metabolic disorders render the liver highly susceptible to injury due to a combination of insulin resistance, lipotoxicity, oxidative stress, mitochondrial dysfunction, ER stress, and chronic inflammation. These factors converge to lower the threshold for hepatocellular injury in response to drugs, ischemia, or toxins. Understanding the mechanistic basis of this vulnerability is essential for risk stratification, preventive strategies, and the development of targeted therapies. Effective management of glycemia, lipid levels, oxidative stress, and inflammation can reduce hepatic susceptibility, improving outcomes in diabetic patients. Future research integrating molecular insights with clinical strategies holds promise for protecting the diabetic liver and mitigating injury in this high-risk population.

REFERENCES

1. Kalra A, Yetiskul E, Wehrle CJ, et al. Physiology, Liver. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535438/
2. Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017 Nov 6;27(21):R1147-R1151. doi: 10.1016/j.cub.2017.09.019. PMID: 29112863; PMCID: PMC5897118.
3. Uti DE, Atangwho IJ, Alum EU, Egba SI, Ugwu OPC, Ikechukwu GC. Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 2025;20(3). doi:10.1177/1934578x251323393

4. Eze Chukwuka W., Egba Simeon, Nweze Emeka I., Ezeh Richard C. and Ugwudike Patrick. Ameliorative Effects of *Allium cepa* and *Allium sativum* on Diabetes Mellitus and Dyslipidemia in Alloxan-induced Diabetic *Rattus novergicus*. *Trends Applied Sci Res*, 2020; 15(2): 145-150
5. Ogugua Victor Nwadiogbu., Agu Obiora Uroko., Egba, Simeon Ikechukwu and Robert Ikechukwu. Modulation of Blood Glucose Concentration, Lipid Profile and Haematological Parameters in Alloxan Induced Diabetic Rats Using Methanol Extract of *Nauclea latifolia* Root Bark. *Asian Journal of Biological Sciences*, 2017; 10(1): 1-8
6. Alum, E.U. Circadian nutrition and obesity: timing as a nutritional strategy. *J Health Popul Nutr* **44**, 367 (2025). https://doi.org/10.1186/s41043-025-01102-y
7. Izah, S.C., Betiang, P.A., Ugwu, O.P.C., Ainebyoona, C., Uti, D.E., Echegu, D.A. The Ketogenic Diet in Obesity Management: Friend or Foe?. *Cell Biochem Biophys* (2025). https://doi.org/10.1007/s12013-025-01878-0
8. Jha BK, Sherpa ML, Imran M, Mohammed Y, Jha LA, Paudel KR, Jha SK. Progress in Understanding Metabolic Syndrome and Knowledge of Its Complex Pathophysiology. Diabetology. 2023; 4(2):134-159. https://doi.org/10.3390/diabetology4020015
9. Tirosh O. Hypoxic Signaling and Cholesterol Lipotoxicity in Fatty Liver Disease Progression. Oxid Med Cell Longev. 2018 May 31;2018:2548154. doi: 10.1155/2018/2548154. PMID: 29955245; PMCID: PMC6000860.
10. Hwang JS, Lai TH, Kim DR. Targeting Lipophagy in Liver Diseases: Impact on Oxidative Stress and Steatohepatitis. Antioxidants. 2025; 14(8):908. https://doi.org/10.3390/antiox14080908
11. Contreras-Zentella ML, Hernández-Espinosa LC, Hernández-Muñoz R. Oxidative Stress in Liver Metabolic Dysfunction and Diseases, with a Focus on Hepatogenic Diabetes: Effect of Alcohol Consumption. Antioxidants. 2025; 14(12):1494. https://doi.org/10.3390/antiox14121494
12. Alum, E.U., Uti, D.E. & Offor, C.E. Redox Signaling Disruption and Antioxidants in Toxicology: From Precision Therapy to Potential Hazards. *Cell Biochem Biophys* (2025). https://doi.org/10.1007/s12013-025-01846-8
13. Qiu Y, Chang S, Zeng Y, Wang X. Advances in Mitochondrial Dysfunction and Its Role in Cardiovascular Diseases. Cells. 2025; 14(20):1621. https://doi.org/10.3390/cells14201621
14. Nur Azan NI, Abdul Karim N, Sulaiman N, Ng MH, Najib AM, Hassan H, Alias E. Oxidative Stress and Mitochondrial Dysfunction in Cardiovascular Aging: Current Insights and Therapeutic Advances. Biomedicines. 2026 Jan 3;14(1):100. doi: 10.3390/biomedicines14010100. PMID: 41595638; PMCID: PMC12838834.
15. Shi S, Wang L, van der Laan LJW, Pan Q, Verstegen MMA. Mitochondrial Dysfunction and Oxidative Stress in Liver Transplantation and Underlying Diseases: New Insights and Therapeutics. Transplantation. 2021 Nov 1;105(11):2362-2373. doi: 10.1097/TP.0000000000003691. PMID: 33577251; PMCID: PMC9005104.
16. Iacobini C, Vitale M, Pesce C, Pugliese G, Menini S. Diabetic Complications and Oxidative Stress: A 20-Year Voyage Back in Time and Back to the Future. Antioxidants. 2021; 10(5):727. https://doi.org/10.3390/antiox10050727
17. Araki E, Nishikawa T. Oxidative stress: A cause and therapeutic target of diabetic complications. J Diabetes Investig. 2010 Jun 1;1(3):90-6. doi: 10.1111/j.2040-1124.2010.00013.x. PMID: 24843413; PMCID: PMC4008021.
18. Chen Y, Liu X, Liu Y, Li Y, Li D, Mei Z, Deng Y. Mitochondrial quality control in diabetes mellitus and complications: molecular mechanisms and therapeutic strategies. Cell Death Dis. 2025 Aug 27;16(1):652. doi: 10.1038/s41419-025-07936-y. Erratum in: Cell Death Dis. 2025 Dec 23;16(1):906. doi: 10.1038/s41419-025-08078-x. PMID: 40866350; PMCID: PMC12391366.
19. He Z, Liu Q, Wang Y, Zhao B, Zhang L, Yang X, Wang Z. The role of endoplasmic reticulum stress in type 2 diabetes mellitus mechanisms and impact on islet function. PeerJ. 2025 Mar 28;13:e19192. doi: 10.7717/peerj.19192. PMID: 40166045; PMCID: PMC11956770.
20. Villafan-Bernal JR, Barajas-Olmos F, Guzmán-Guzmán IP, Martínez-Hernández A, Contreras-Cubas C, García-Ortiz H, Morales-Rivera MI, Martínez-Portilla RJ, Orozco L. Relevant Serum Endoplasmic Reticulum Stress Biomarkers in Type 2 Diabetes and Its Complications: A Systematic Review and Meta-Analysis. Antioxidants. 2024; 13(12):1564. https://doi.org/10.3390/antiox13121564
21. Maiers JL, Malhi H. Endoplasmic Reticulum Stress in Metabolic Liver Diseases and Hepatic Fibrosis. Semin Liver Dis. 2019 May;39(2):235-248. doi: 10.1055/s-0039-1681032. Epub 2019 Mar 25. PMID: 30912096; PMCID: PMC6530577.
22. Slevin E, Baiocchi L, Wu N, Ekser B, Sato K, Lin E, Ceci L, Chen L, Lorenzo SR, Xu W, Kyritsi K, Meadows V, Zhou T, Kundu D, Han Y, Kennedy L, Glaser S, Francis H, Alpini G, Meng F. Kupffer Cells:

Inflammation Pathways and Cell-Cell Interactions in Alcohol-Associated Liver Disease. Am J Pathol. 2020 Nov;190(11):2185-2193. doi: 10.1016/j.ajpath.2020.08.014. Epub 2020 Sep 11. PMID: 32919978; PMCID: PMC7587925.

23. Li X, Gao P, Niu J. Metabolic Comorbidities and Risk of Development and Severity of Drug-Induced Liver Injury. Biomed Res Int. 2019 Aug 18;2019:8764093. doi: 10.1155/2019/8764093. PMID: 31531370; PMCID: PMC6720367.
24. Tiwari V, Shandily S, Albert J, Mishra V, Dikkatwar M, Singh R, Sah SK, Chand S. Insights into medication-induced liver injury: Understanding and management strategies. Toxicol Rep. 2025 Mar 1;14:101976. doi: 10.1016/j.toxrep.2025.101976. Erratum in: Toxicol Rep. 2025 Jun 16;14:102068. doi: 10.1016/j.toxrep.2025.102068. PMID: 40125297; PMCID: PMC11928981.
25. Ogbonna OA., Egba, SI., Uhuo EN., Omeoga HC., Obeagu EI. Toxic outcomes of ciprofloxacin and gentamicin co-administration and possible ameliorating role for antioxidant vitamins C and E in Wistar Rats. Elite Journal of Medicine, 2024; 2(3): 1-14.
26. Iheagwam FN, Joseph AJ, Adedoyin ED, Iheagwam OT, Ejoh SA. Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight. Pathophysiology. 2025 Feb 13;32(1):9. doi: 10.3390/pathophysiology32010009. PMID: 39982365; PMCID: PMC12077258.
27. García-Compeán D, Orsi E, Kumar R, Gundling F, Nishida T, Villarreal-Pérez JZ, Del Cueto-Aguilera ÁN, González-González JA, Pugliese G. Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives. World J Gastroenterol. 2022 Feb 28;28(8):775-793. doi: 10.3748/wjg.v28.i8.775. PMID: 35317103; PMCID: PMC8900578.
28. Mahmoud MR, Ibrahim S, Shahien MM, Alshammari AD, Alenazi FS, Alreshidi F, Aljadani A, Abdel Khalik A, Elhaj AH, Khalifa AM, et al. Comparison Between the Impact of Diabetes Mellitus on Liver Diseases and Vice Versa Among Saudi and Egyptian Patients. Healthcare. 2025; 13(4):376. https://doi.org/10.3390/healthcare13040376
29. Mohan A, Hasan ZW, Galani HG, Afroze T, Niazi RK, Alfaki R, Shahzadi A, Lal PM, Aminpoor H, Karimi H, Kumar V, Tejwaney U, Kumar S. Diabetes and liver cirrhosis: shared pathways and clinical implications - a narrative review. Ann Med Surg (Lond). 2025 Oct 7;87(12):8418-8425. doi: 10.1097/MS9.0000000000004012. PMID: 41377337; PMCID: PMC12688777.
30. Ugwu, O. P. C., Alum, E. U. and Uhama, K. C. (2024). Dual Burden of Diabetes Mellitus and Malaria: Exploring the Role of Phytochemicals and Vitamins in Disease Management. Research Invention Journal of Research in Medical Sciences. 3(2):38-49.
31. Yan Q, Liu S, Sun Y, Chen C, Yang S, Lin M, Long J, Yao J, Lin Y, Yi F, Meng L, Tan Y, Ai Q, Chen N, Yang Y. Targeting oxidative stress as a preventive and therapeutic approach for cardiovascular disease. J Transl Med. 2023 Aug 2;21(1):519. doi: 10.1186/s12967-023-04361-7. PMID: 37533007; PMCID: PMC10394930.
32. Manful CF, Fordjour E, Ikumoinein E, Abbey L, Thomas R. Therapeutic Strategies Targeting Oxidative Stress and Inflammation: A Narrative Review. BioChem. 2025; 5(4):35. https://doi.org/10.3390/biochem5040035
33. Poljsak B. Strategies for reducing or preventing the generation of oxidative stress. Oxid Med Cell Longev. 2011;2011:194586. doi: 10.1155/2011/194586. Epub 2011 Dec 10. PMID: 22191011; PMCID: PMC3236599.
34. Yamada Y, Takano Y, Satrialdi, Abe J, Hibino M, Harashima H. Therapeutic Strategies for Regulating Mitochondrial Oxidative Stress. Biomolecules. 2020; 10(1):83. https://doi.org/10.3390/biom10010083
35. Otero Sanchez L, Chen Y, Lassailly G, Qi X. Exploring the links between types 2 diabetes and liver-related complications: A comprehensive review. United European Gastroenterol J. 2024 Mar;12(2):240-251. doi: 10.1002/ueg2.12508. Epub 2023 Dec 16. PMID: 38103189; PMCID: PMC10954434.
36. Sugandh F, Chandio M, Raveena F, Kumar L, Karishma F, Khuwaja S, Memon UA, Bai K, Kashif M, Varrassi G, Khatri M, Kumar S. Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine. Cureus. 2023 Aug 18;15(8):e43697. doi: 10.7759/cureus.43697. PMID: 37724233; PMCID: PMC10505357.
37. Batir-Marin D, Ştefan CS, Boev M, Gurău G, Popa GV, Matei MN, Ursu M, Nechita A, Maftei N-M. A Multidisciplinary Approach of Type 1 Diabetes: The Intersection of Technology, Immunotherapy, and Personalized Medicine. Journal of Clinical Medicine. 2025; 14(7):2144. https://doi.org/10.3390/jcm14072144
38. Su J, Yang L, Sun Z, Zhan X. Personalized Drug Therapy: Innovative Concept Guided With Proteoformics. Mol Cell Proteomics. 2024 Mar;23(3):100737. doi: 10.1016/j.mcpro.2024.100737. Epub 2024 Feb 13. PMID: 38354979; PMCID: PMC10950891.

39. Edvardsson M, Heenkenda MK. Precision Medicine: Personalizing Healthcare by Bridging Aging, Genetics, and Global Diversity. Healthcare. 2025; 13(13):1529. https://doi.org/10.3390/healthcare13131529

CITE AS: Muhindo Anitah (2026). Impact of Metabolic Disease on Hepatic Vulnerability: Why Diabetic Livers Injure More Easily. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES, 7(2):146-151.
https://doi.org/10.59298/NIJSES/2026/72.146151